MX2020010722A - Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. - Google Patents

Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.

Info

Publication number
MX2020010722A
MX2020010722A MX2020010722A MX2020010722A MX2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A
Authority
MX
Mexico
Prior art keywords
antibodies
graft rejection
prevention
therapies
kits
Prior art date
Application number
MX2020010722A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Espie
James Rush
Boerje Haraldsson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020010722A publication Critical patent/MX2020010722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020010722A 2018-04-13 2019-04-11 Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. MX2020010722A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
EP18208332 2018-11-26
PCT/IB2019/052976 WO2019198019A1 (en) 2018-04-13 2019-04-11 Anti-cd40 antibodies for use in prevention of graft rejection

Publications (1)

Publication Number Publication Date
MX2020010722A true MX2020010722A (es) 2020-11-06

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010722A MX2020010722A (es) 2018-04-13 2019-04-11 Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.

Country Status (13)

Country Link
US (2) US11780927B2 (enExample)
EP (1) EP3774913A1 (enExample)
JP (2) JP6861301B2 (enExample)
KR (1) KR20200143718A (enExample)
CN (1) CN111971307A (enExample)
AU (1) AU2019252858A1 (enExample)
BR (1) BR112020020277A2 (enExample)
CA (1) CA3094600A1 (enExample)
CL (1) CL2020002622A1 (enExample)
IL (1) IL277828A (enExample)
MX (1) MX2020010722A (enExample)
TW (1) TW201943731A (enExample)
WO (1) WO2019198019A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020267953A1 (en) * 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
JP2023548812A (ja) * 2020-10-26 2023-11-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫抑制剤の曲線下面積を評価する方法ならびに関連する方法及びシステム
CN118234749A (zh) * 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
KR20260116248A (ko) * 2023-11-28 2026-07-28 엘레던 파마슈티컬즈, 아이엔씨. 이식 거부반응 예방을 위한 방법 및 조성물
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
RU2006141632A (ru) * 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
IL277828A (en) 2020-11-30
US20240287198A1 (en) 2024-08-29
BR112020020277A2 (pt) 2021-01-19
CL2020002622A1 (es) 2021-04-16
JP6861301B2 (ja) 2021-04-21
EP3774913A1 (en) 2021-02-17
JP2021113190A (ja) 2021-08-05
US20210079107A1 (en) 2021-03-18
CN111971307A (zh) 2020-11-20
JP2020519634A (ja) 2020-07-02
KR20200143718A (ko) 2020-12-24
TW201943731A (zh) 2019-11-16
AU2019252858A1 (en) 2020-10-08
WO2019198019A1 (en) 2019-10-17
US11780927B2 (en) 2023-10-10
CA3094600A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EP4442278A3 (en) Humanized antibodies against c-kit
JOP20200309A1 (ar) أجسام مضادة لـ il-11
PH12020552229A1 (en) Il-11ra antibodies
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
MY203971A (en) Anti-lag-3 antibodies and compositions
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
PH12020551292A1 (en) Moscato wine replicas produced from individual components
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
PH12018502586A1 (en) Anti-coagulation factor xi antibodies
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
ZA202309516B (en) Anti-ccr8 antibodies
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EP4588484A3 (en) Methods of treating multiple myeloma
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
EP4640698A3 (en) Antibodies to mucin-16 and methods of use thereof